ArticleJournal of thoracic disease2018
"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not?
Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.JAMA oncology · 2020Pooled it
- Incidence of and risk factors for immune checkpoint inhibitor-related pneumonitis in thoracic malignancies: a prospective multicenter study.The oncologist · 2026Observational
- The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies.Clinical and experimental medicine · 2025Review
- A Real-World Comparison of the Safety Profile for Immune Checkpoint Inhibitors in Oncology Patients.Journal of clinical medicine · 2025Article
- Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report.Frontiers in immunology · 2025Article
- Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events.Frontiers in immunology · 2024Review
- Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.Journal for immunotherapy of cancer · 2023Article
- Review
- The role of PD-1 signaling in health and immune-related diseases.Frontiers in immunology · 2023Review
- Immune checkpoint inhibitors in lymphoma: challenges and opportunities.Annals of translational medicine · 2021Review
- Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120.Frontiers in pharmacology · 2021Article
- Article
- Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer.BMJ case reports · 2020Article
- A Review of T-Cell Related Therapy for Osteosarcoma.International journal of molecular sciences · 2020Review
- Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer.Frontiers in oncology · 2020Review
- The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules.Molecules (Basel, Switzerland) · 2019Article
- Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC.Cell transplantationReview
- Severe Immune-related Adverse Events and Their Effect on Survival in Patients With Advanced Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors.Cancer diagnosis & prognosisArticle
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.